APE1.F Addex Therapeutics Ltd
- Market cap
- EUR 4.42M
- P/E
- -
- P/B
- 2.11x
- ROE
- -362.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is APE1.F undervalued?
Graham numberThe Graham number of Addex Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Addex Therapeutics Ltd fundamental analysis
No fundamental analysis for Addex Therapeutics Ltd yet.
Addex Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for un…
Full company profileAddex Therapeutics Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Addex Therapeutics Ltd annual financial statements (CHF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.92M | 1.42M | 1.61M | 404K | 30.0K | 0.00 |
| Operating Income | -15.5M | -10.5M | -2.24M | -2.76M | -2.81M | -2.25M |
| EBITDA | - | -10.5M | -2.19M | -4.65M | -6.83M | -6.84M |
| Net Income | -15.4M | -20.8M | -10.6M | 7.06M | -6.73M | -6.91M |
| EPS | -0.41 | -0.27 | -0.08 | 0.05 | -0.06 | -0.05 |
| Balance Sheet | ||||||
| Total Assets | 22.5M | 8.28M | 4.64M | 10.7M | 6.36M | 3.48M |
| Total Liabilities | 5.61M | 3.37M | 3.50M | 1.00M | 1.60M | 1.57M |
| Shareholders' Equity | 16.9M | 4.91M | 1.15M | 9.68M | 4.77M | 1.91M |
| Cash & Short-term Investments | 20.5M | 6.96M | 3.87M | 3.34M | 1.64M | 767K |
| Cash Flow | ||||||
| Operating Cash Flow | -14.7M | -16.4M | -7.99M | -5.37M | -2.17M | -2.47M |
| Capital Expenditure | 31.5K | 581.00 | 6.84K | 1.27K | 0.00 | 0.00 |
| Free Cash Flow | -14.7M | -16.4M | -8.00M | -5.37M | -2.17M | -2.47M |
| Ratios | ||||||
| ROE | -90.7% | -423.5% | -921.6% | 72.9% | -141.2% | -362.2% |
| ROA | -68.1% | -251.2% | -227.4% | 66.1% | -105.7% | -198.6% |
| Net Profit Margin | -526.4% | -1,462.6% | -654.5% | 1,746.0% | -22,448.4% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Addex Therapeutics Ltd dividends
Addex Therapeutics Ltd has not paid dividends in the last 5 fiscal years.
Last stock split: 1:20 on Oct 23, 2023.
Who owns Addex Therapeutics Ltd
- Insiders 0.00%
- Institutions 0.14%
- Public & others 99.87%
- Shares outstanding 1.75M
- Free float 466K
Addex Therapeutics Ltd company profile
- Company name
- Addex Therapeutics Ltd
- Ticker
- APE1.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- Chemin des Mines, 9, Geneva, Switzerland, 1202
- Phone
- 41 22 884 1555
- Website
- addextherapeutics.com
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Addex Therapeutics Ltd management
4- Mr. Timothy Mark DyerCo-Founder, CEO & Director · born 1968
- Dr. Roger G. Mills M.D.Chief Medical Officer & Director · born 1957
- Mr. Lénaic TeyssédouHead of Finance · born 1985
- Dr. Jean-Philippe Rocher Ph.D.Head of Pharmaceutical Development & Member of Executive Management · born 1959